HHS, DEA both rule in favor of kratom, against FDA
Jan 28, 2021, American Kratom Association
- The Food and Drug Administration (FDA) recommended that Kratom be classified as a Schedule 1 drug on Aug. 31, 2016.
- A Schedule 1 drug is a substance that has “a high potential for abuse,” no “currently accepted medical treatment use in the U.S.,” and a “lack of accepted safety for use under medical supervision.”
- The FDA’s 2016 recommendation was blocked by the Drug Enforcement Agency (DEA) two weeks later (Oct. 13, 2016).
- The FDA resubmitted its recommendation a year later (October 17, 2017).
- The Department of Health and Human Services (HHS) withdrew the FDA’s second recommendation a year after that (Aug. 16, 2018).
- HHS said that categorizing kratom as a Schedule 1 drug posed “significant risk of immediate adverse public health consequences” to millions of kratom users.
- Kratom is used by opioid addicts in withdrawing from the often-lethal opium-based substances.
- According to kratom advocates and Mac Haddow, a spokesperson for the American Kratom Association (AKA), the FDA failed to make the HHS action public. Instead, the agency allowed policy makers to believe its recommendation was being actively considered by the DEA.
- The withdrawal of the recommendation was discovered by Congressman Mark Pocan (D-WI) and Congressman Morgan Griffith (R-VA) in their oversight roles of HHS.
Original article: http://bit.ly/FDAkratom